Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kg
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Fungal Infection
Conditions
Invasive Fungal Infection
Trial Timeline
Feb 22, 2022 → Dec 31, 2026
NCT ID
NCT04665037About Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kg
Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kg is a phase 2 stage product being developed by Merck for Invasive Fungal Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04665037. Target conditions include Invasive Fungal Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04665037 | Phase 2 | Recruiting |
Competing Products
20 competing products in Invasive Fungal Infection